Healthtech Startup Entvin AI Bags Funding from Y Combinator

With this funding, Entvin plans to expand its AI capabilities & accelerate customer acquisition among mid-to-large pharmaceutical companies globally.

Entvin AI has secured INR 5 Cr funding from startup accelerator Y Combinator.

Founded by three IIT Bombay graduates,the startup provides specialized AI solutions for pharmaceutical and life sciences companies worldwide. 

Sanskar Jain, Co-Founder & CEO of Entvin, said, "We identified a significant opportunity to transform how life sciences companies navigate regulatory requirements. Regulatory professionals spend countless hours on documentation, compliance checks, and staying updated with constantly evolving FDA guidelines. Our AI agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens."

Financial Plan

Entvin AI has reportedly secured $500K in its initial funding round, reflecting a competitive 0.1% acceptance rate. The startup plans to use this funding to enhance its AI capabilities and accelerate customer acquisition among mid-to-large pharmaceutical firms globally.

Founded by Sanskar Jain, Hemant Phalak, and Rishabh Arya, Entvin AI has created a platform that simplifies the complex and resource-intensive FDA drug approval process.

Sharing thoughts, Hemant Phalak, Co-Founder & CPO, said, “At Entvin, our AI agents seamlessly integrate into existing workflows to enhance efficiency and accelerate decision-making. Our platform doesn't just organize information - it actively identifies compliance gaps, automates repetitive documentation tasks, and provides regulatory teams with actionable insights in real-time. This helps life science companies navigate the approval process with unprecedented efficiency while maintaining trust, reliability and seamless integration.

Early pilot customers have shown positive results, indicating that the AI solution can save substantial time for regulatory and scientific teams while enhancing compliance accuracy—an essential aspect in an industry where regulatory errors can incur significant financial repercussions.

Entvin AI aims to tackle this challenge by offering a specialized platform for regulatory teams that automates tasks such as document drafting, compliance verification, and regulatory monitoring.

Further, its architecture utilizes large language models fine-tuned for regulatory documentation and FDA compliance, resulting in increased efficiency, with some teams reporting the recovery of hundreds of hours previously absorbed by manual processes.

Explaining their approach, Rishabh Arya, Co-Founder & CTO of Entvin, said, "We've developed an AI system that deeply understands the complex language of FDA regulations and can process massive volumes of regulatory documentation. Our architecture is enterprise-grade, designed to meet the highest compliance standards required by pharmaceutical companies like SOC 2, ISO 2700."

Stay tuned for more such updates on Digital Health News.